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Abstract
Background: Transcriptional silencing associated with aberrant promoter methylation has been
established as an alternate pathway for the development of cancer by inactivating tumor suppressor
genes. TMS1 (Target of Methylation induced Silencing), also known as ASC (Apoptosis Speck like
protein containing a CARD) is a tumor suppressor gene which encodes for a CARD (caspase
recruitment domain) containing regulatory protein and has been shown to promote apoptosis
directly and by activation of downstream caspases. This study describes the methylation induced
silencing of TMS1/ASC gene in prostate cancer cell lines. We also examined the prevalence of TMS1/
ASC gene methylation in prostate cancer tissue samples in an effort to correlate race and clinico-
pathological features with TMS1/ASC gene methylation.
Results:  Loss of TMS1/ASC  gene expression associated with complete methylation of the
promoter region was observed in LNCaP cells. Gene expression was restored by a demethylating
agent, 5-aza-2'deoxycytidine, but not by a histone deacetylase inhibitor, Trichostatin A. Chromatin
Immunoprecipitation (ChIP) assay showed enrichment of MBD3 (methyl binding domain protein 3)
to a higher degree than commonly associated MBDs and MeCP2. We evaluated the methylation
pattern in 66 prostate cancer and 34 benign prostatic hyperplasia tissue samples. TMS1/ASC gene
methylation was more prevalent in prostate cancer cases than controls in White patients (OR 7.6,
p 0.002) while no difference between the cases and controls was seen in Black patients (OR 1.1, p
0.91).
Conclusion:  Our study demonstrates that methylation-mediated silencing of TMS1/ASC  is a
frequent event in prostate cancer, thus identifying a new potential diagnostic and prognostic marker
for the treatment of the disease. Racial differences in TMS1/ASC methylation patterns implicate the
probable role of molecular markers in determining in susceptibility to prostate cancer in different
ethnic groups.
Published: 18 July 2006
Molecular Cancer 2006, 5:28 doi:10.1186/1476-4598-5-28
Received: 04 January 2006
Accepted: 18 July 2006
This article is available from: http://www.molecular-cancer.com/content/5/1/28
© 2006 Das et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
Page 2 of 10
(page number not for citation purposes)
Background
Gene silencing associated with aberrant promoter methyl-
ation has been suggested as an alternate pathway for
development of cancer [1]. This form of epigenetic change
contributes to tumor initiation and progression by tran-
scriptional silencing of tumor-suppressor genes. Several
genes have been shown to be epigenetically inactivated in
a wide range of tumors [2] and most neoplasms show
hypermethylation of one or more genes [3-5]. This has led
to the concept of a 'hypermethylation profile' of tumors
which could have potential clinical applications [5-7].
The hypermethylated genes can be broadly classified as
those involved in cell cycle regulation (p16INK4a, p15,
Rb), genes associated with DNA repair (BRCA1, MGMT),
apoptosis (DAPK), and drug detoxification (GSTPi), drug
resistance (MGMT), cellular differentiation, angiogenesis
(THBS1) and metastasis (E-cadherin) [2].
Epigenetic dysregulation of an apoptotic pathway appears
to be connected to the development of many cancers as
confirmed by several research communications [8,9].
Apoptosis or 'programmed cell death' is essential for
embryonic development and also plays an important role
in the immune system and maintenance of cellular home-
ostasis [10]. A defect in apoptosis is implicated in neuro-
degenerative diseases, autoimmunity, and cancer and in
chemo-resistance. Multiple genes direct the apoptotic
pathway to restrain the inappropriate proliferation of cells
and a defect in the signaling mechanism gives the cancer
cells an added survival advantage leading to tumor initia-
tion, progression and even drug resistance. Apoptosis is
mediated by a family of cystine proteases called caspases.
There are two groups of caspases – the initiator caspases
(CASP8, CASP9 and CASP10) and the effector caspases
(CASP3, CASP6 and CASP7). Caspases exist as latent pro-
enzymes and are activated by proteolytic cleavage. Several
key genes involved in apoptosis have been showed to be
target of epigenetic changes [9].
Recently, TMS1 was shown to be aberrantly hypermethyl-
ated in breast cancer tissues and cell lines [11]. This gene
is also known as ASC (Apoptosis Speck Like protein con-
taining a CARD) [12]. TMS1/ASC  encodes a 22-kDa
CARD protein and promotes apoptosis in a caspase 9
dependent pathway. TMS1/ASC has been shown to bind
with various proteins like Pyrin, Ipaf and copyrin/
PYPAF1[12]. In addition to its role in cancer development
there is ample evidence which suggests that TMS1/ASC is
involved in immune responses and NF-κB and caspase1
activation [13,14]. The downregulation of TMS1/ASC in
breast cancer cell lines correlates with dense methylation
on the CpG islands. Methylation of the promoter region
of TMS1/ASC has also been identified in small cell lung
cancer and non-small cell lung cancer [15], human gliob-
lastoma [16], ovarian tumors [17,18], colorectal cancer
[19], neuroblastoma [20], and melanoma [21]. However
in a study by Roman-Gomez et. al., on acute lymphoblas-
tic leukemia patients no correlation was found with meth-
ylation of the TMS1/ASC gene [22].
So far no studies have been reported on the role of TMS1/
ASC in prostate cancer. In this study we examined the
mechanism of TMS1/ASC gene silencing in prostate can-
cer cell lines. We also studied the prevalence of TMS1/ASC
gene methylation in prostate cancer tissue samples as well
as the association of race and clinico-pathological features
with TMS1/ASC gene methylation.
Results
Expression and methylation status of TMS1/ASC gene in 
prostate cancer cell lines
By RTPCR (reverse transcriptase polymerase chain reac-
tion), we first analyzed the expression status of TMS1/ASC
in three prostate cancer cell lines – LNCaP, PC3 and
DU145 by RT-PCR. LNCaP exhibited complete loss of
TMS1/ASC  transcript whereas partial expression was
detected in the remaining two cell lines (Fig 1). β-actin
was used as control for RNA integrity and loading.
Methylation-mediated deregulation of TMS1/ASC  has
been described in breast cancer and in other tumors. To
determine if methylation was responsible for down regu-
lation of TMS1/ASC in prostate cancer cell lines, we per-
formed MS-PCR (methylation specific PCR) using both
methylated and unmethylated primers (Fig 2C). Com-
plete methylation of the promoter region was seen in
LNCaP cells whereas PC3 and DU145 showed partial
methylation of the TMS1/ASC gene (Fig 2D). TMS1/ASC
expression inversely correlated with the methylation sta-
tus. To confirm our MS-PCR findings we performed
bisulfite genomic sequencing of the sodium bisulfite
modified DNA in the three cell lines. In LNCaP cell line
the cytosines in the non-CpG sites were converted to thy-
midine but the cytosines associated with CpG islands
Expression pattern of TMS1/ASC gene Figure 1
Expression pattern of TMS1/ASC gene. Reverse transcription 
PCR analysis showing expression of TMS1/ASC gene in pros-
tate cancer cell lines. β-actin was used as a control for RNA 
integrity. NC-negative control, PC-positive control.Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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remained unmodified after bisulfite treatment thereby
demonstrating complete methylation. PC3 and DU145
showed a mixed pattern of methylated as well as unmeth-
ylated cytosine in the CpG dinucleotides (Fig 2E). We also
performed MS-PCR on DNA extracted from 5 representa-
tive tissue samples of prostate cancer patients. Two of the
samples showed complete methylation, while the remain-
ing three showed partial methylation of TMS1/ASC gene
promoter (Fig 2F).
5-Aza-2'-deoxycytidine and TSA treatment of LNCaP cell 
line
We treated LNCaP cells with 5-Aza-2'-deoxycytidine in an
attempt to induce TMS1/ASC gene expression. 5-Aza-2'-
deoxycytidine is a demethylating agent and forms a cova-
lent complex with DNA methyltransferase thus inhibiting
DNA methylation. The TMS1/ASC gene expression was
examined by RT-PCR analysis and methylation status of
TMS1/ASC  gene examined by MS-PCR of the bisulfite
modified drug treated DNA. Following 5-Aza-2'-deoxycy-
tidine treatment the TMS1/ASC gene underwent partial
Methylation pattern of TMS1/ASC Figure 2
Methylation pattern of TMS1/ASC. Panel A – graphical representation of the structure of TMS1/ASC gene showing position of 
the three exons. Panel B shows the location of the CpG dinucleotides. Panel C shows the postion of the primers used for MS-
PCR and bisulfite sequencing in the promoter region of TMS1/ASC. Positions are indicated relative to translation start site. 
Panel D shows MS-PCR analysis of TMS1/ASC gene on the different prostate cancer cell lines. LNCaP exhibits complete methyl-
ation of TMS1/ASC gene. PC3 and Du145 have both the methylated as well as the unmethylated allele and are consequently 
expressed. NC-negative control, U-unmethylated allele, M-methylated allele. The methylation pattern correlates with the 
bisulfite genomic sequencing shown on panel E. Completely methylated cytosines (black arrow) in LNCaP are not converted to 
thymidine following bisulfite treatment and show up on the C lane whereas partially methylated cytosines in the CpG's are 
seen both in the T lane as well as in the C lane in PC3 and Du145 cell lines. Positions are indicated relative of the translation 
start site. Panel F shows representative examples of 5 prostate cancer tissue samples analyzed by MS-PCR and gel electro-
phoresis. Presence of a band in lanes marked as UM indicates presence of unmethylated allele and a band in the lanes marked 
M denotes a methylated allele; NC-negative control; PC-positive control.Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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demethylation and resulted in expression of the gene (Fig
3). Since methylated DNA binds to methylcytosine bind-
ing proteins which in turn interact with histone deacety-
lases (HDAC), we treated the LNCaP cells with a histone
deacetylase inhibitor TSA to see if it can induce expression
of the TMS1/ASC gene. TSA treatment failed to induce
TMS1/ASC  mRNA expression in LNCaP cells (Fig 3A).
Methylation pattern analysis of drug treated cells showed
that TMS1/ASC promoter remained fully methylated in
TSA-treated cells whereas both unmethylated and methyl-
ated alleles exist in 5-AZA-2'-deoxycytidine treated cells
(Fig. 3B).
Histone acetylation and interaction of methylcytosine 
binding proteins with TMS1/ASC promoter in LNCaP cell 
line
Recent studies have shown that deacetylation of histone
H3 and H4 by the HDAC's presumably leads to the forma-
tion of a chromatin environment that inhibits transcrip-
tion. To determine if methylation induced silencing of
TMS1/ASC is associated with changes in histone acetyla-
tion pattern we studied the pattern of histone acetylation
at the TMS1/ASC promoter in LNCaP cells using ChIP
assay. Neither acetylated H3 nor acetylated H4 binds to
TMS1/ASC  promoter region in LNCaP (Fig 4A). Since
methylcytosine binding proteins mediate the repressive
effect of methylated DNA, we examined the interaction of
methylcytosine binding proteins with the TMS1/ASC pro-
moter. The TMS1 promoter interacted mainly with MBD3
though minimal binding of MBD1, MBD2 and MeCP2 at
TMS1/ASC promoter was also seen (Fig 4B).
Patient characteristics and association with TMS1/ASC 
gene methylation
Table 2 shows the demographics and clinical characteris-
tics of the study subjects. The prostate cancer patients (51
– 80 yrs) were 7 years younger than BPH (53–88 yrs) on
an average. However the racial distribution was similar.
Most of the patients were stage 2–3 and had Gleason score
of 6–7. Table 3 shows the frequency of TMS1/ASC gene
methylation in all the samples examined. TMS1/ASC gene
methylation was seen in 63.6% of prostate cancer but in
only 35.3% of BPH patients with an age-adjusted odds
ratio of 3.7 (95% CI 1.4 – 9.4). The prevalence of TMS1/
ASC  gene methylation in prostate cancer patients was
found to be similar in both races (66.7% in Blacks as com-
pared to 62.2% in Whites). However comparing the prev-
alence of TMS1/ASC methylation between prostate-cancer
patients and controls, there was no difference among
Expression and methylation pattern of TMS1/ASC gene in  drug treated LNCaP cells and in Tumor tissues Figure 3
Expression and methylation pattern of TMS1/ASC gene in 
drug treated LNCaP cells and in Tumor tissues. Panel A 
shows restoration of TMS1/ASC gene expression following 
treatment with 5-Aza but not with TSA alone. Panel B – MS-
PCR analysis on the drug treated LNCaP cells confirm 
expression of TMS1/ASC is associated with partial demethyla-
tion of the gene seen as a band on the UM lane in 5-Aza 
treated cells. Presence of a band in lanes marked as UM indi-
cates presence of unmethylated allele and a band in the lanes 
marked M denotes a methylated allele. NC-negative control; 
PC-positive control; UM-unmethylated allele; M-methylated 
allele; LN-C-untreated LNCaP cells; LN-AZA -5-AZA-2'-
deoxycytidine treated cells; LN-AT – 5-AZA-2'-deoxycyti-
dine followed by TSA; LN-TSA – TSA treated cells.
Binding pattern of acetylated histones (panel A) and MBD's  (panel B) to the methylated TMS1/ASC gene Figure 4
Binding pattern of acetylated histones (panel A) and MBD's 
(panel B) to the methylated TMS1/ASC gene. Chromatin 
immunoprecipitation performed on formalin fixed and soni-
cated LNCaP chromatin shows enrichment of MBD3 in the 
immunoprecipitated DNA and low levels of acetylated H3 
suggesting deacetylation of H3 in the silenced TMS1/ASC 
gene.Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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Blacks (prevalence 66.7% for patients and 58.3% for con-
trols), whereas in Whites a significant difference was
observed (prevalence 62.2% for prostate cancer cases and
22.7% for BPH controls). The age adjusted odds ratio
comparing cases to controls among White patients was
7.6 (p = 0.002). We also studied the effect of age and
TMS1/ASC  gene methylation but no association with
early or late onset prostate cancer was observed (data not
shown). No association with stage of the disease was
observed but there was a tendency of TMS1/ASC  gene
methylation to be more frequent in tumors having
Gleason score 7 or higher. (Table 4)
Discussion
Our study shows a clear correlation between TMS1/ASC
methylation and silencing of the gene suggesting a role in
prostate cancer cell lines. Re-expression accompanied by
partial demethylation of TMS1/ASC following 5-AZA-2'-
deoxycytidine confirms that methylation is responsible
for transcriptional silencing of this gene. Lack of response
to TSA treatment suggests that histone acetylation does
not play a role in downregulating the expression of TMS1/
ASC. This finding is similar to the results obtained by
Stimson et al[23]. Over expression of TMS1/ASC  was
shown to inhibit cellular proliferation and induce DNA
fragmentation which can be blocked by a caspase inhibi-
tor [24]. In addition, forced reduction in TMS1/ASC pro-
motes cell survival perhaps in a NFκ-B dependent
pathway [25]. This makes it a therapeutic target by use of
demethylating agents alone or in combination with addi-
tional apoptosis inducing drugs.
ChIP analysis showed binding predominantly with MBD3
and only minimal enrichment of the other MBDs and
MeCP2.  Earlier studies have demonstrated that MBD3
does not bind to methylated DNA alone [26,27]. How-
ever, it has a definite role in maintaining methylation.
Recent studies have shown binding of MBD3 to several
genes like cox6c, leng6, bat5 etc. [28]. Wade et al showed
that MBD3 is a subunit of the NuRD complex that has
nucleosome remodeling and histone deacetylase activities
[29]. MBD3 forms a part of the multiprotein NuRD com-
plex and probably has a role as a transcriptional co-repres-
sor. Our finding that MBD3 binds to methylated TMS1/
ASC is contrary to the known pattern of MBD binding by
MBD proteins to methylated DNA. This could be because
MBD3-containing NuRD complexes bind more specifi-
cally to the methylated TMS1/ASC gene [28].
A noteworthy finding in our study was the statistically sig-
nificant difference in the methylation of TMS1/ASC
Table 1: Table showing details of primers used and cycling conditions for MS-PCR, RT-PCR and PCR amplification of the CHIP DNA.
Gene Primer sequence (5'-3') Anneal. Temp. (°C) No. of Cycles
TMS1/ASC methylated F- CGA TTT TGG CGT TTT TCG ACG GTT 65 35
R- CCG CTC ACC CCG CTA CAA CCG C
TMS1/ASC Unmethylated F- TTG TTG GAG GGT AAT GGA TT 58 35
R- CCC ACA AAA ATA CAC CCA TA
TMS1/ASC RT-PCR F- GGA CGC CTT GGC CCT CAC CG 65 35
R- GGC GCG GCT CCA GAG CCC TG
TMS1/ASC CHIP F- GAG TCG GGA GAC CAG AGT GGA 68 50
R- ACA GCA GCT TCA GCTT GAA CTT CTT G
β-actin F- ACC ATG GAT GAT GAT ATC GC 60 30
R- ACA GGC TGG GGT GTT GAA G
GAPDH F- CCC CAC ACA CAT GCA CTT ACC 65 50
R- CCT AGT CCC AGG GCT TTG ATT
Table 2: Characteristics of 66 prostate-cancer patients and 34 
BPH controls.
Prostate cancer Control (BPH)
n% n % P - v a l u e
Race
Black 21 31.8 12 35.3 0.82
White 45 68.2 22 64.7
Stage
II 42 63.6
III 19 28.8
IV 4 6.1
Unknown 1 1.5
Gleason Score
53 4 . 6
62 6 3 9 . 4
73 2 4 8 . 4
83 4 . 6
92 3 . 0
Preoperative 
serum PSA
< 4 5 7.6
4.0 – 8 46 69.7
8.1 – 12 8 12.1
> 12 7 10.6
Mean age (range) 64 yrs (51 – 80) 71 yrs (53 – 88) < 0.001Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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among the cases and controls in Whites compared to
Blacks. We observed an age adjusted odds-ratio of 7.6
(95% CI 2.1–27.3) in Whites as compared to only 1.1
(95% CI 0.2–5.5) among Blacks. Whether this finding
reflects involvement of different pathogenetic pathways in
different races will be interesting to study. In the US, the
incidence and mortality of prostate cancer is about two-
fold higher among Blacks compared to Whites, suggesting
racial differences in prostate tumor occurrence and aggres-
siveness [30]. The reason for these racial differences is not
well understood. It is possible that promoter-region gene
hypermethylation may be influenced by environmental
exposures.
There have been only a few studies on differences in gene
methylation between different races. Two studies by
Woodson et al showed a differential methylation pattern
and expression of CD44 in Blacks and Whites [31,32].
When we examined 5 genes frequently methylated in
prostate cancer (GSTP1, CD44, ECAD, RASSF1A and EBR)
in the same patient population we did not find any signif-
icant differences in the gene specific methylation pattern
between the different races (Table 5). Ethnic group related
differences in hypermethylation of promoter region of
GSTP1 gene were reported in a recent paper [33]. The
authors observed higher hazard ratio (HR) for pathogen-
esis among African Americans as compared to Caucasians.
In contrast to the above observation, we found the hazard
ratio of TMS1/ASC methylation (prostate cancer versus
BPH) to be lower in Blacks as compared to Whites. Ethnic
origin is an important determinant of prostate cancer risk,
incidence, and disease progression. In the US, the African-
American male group has the highest incidence rate for
prostate cancer [30]. Differences in diet, socioeconomic
environment, lifestyle between the two ethnic groups
have been implicated as causative factors for the striking
ethnic differences in the incidence and clinical behavior of
prostate cancer. However, molecular mechanisms under-
lying the racial diversity are not well understood. The
recent report by Fang et. al., shows that Genistein leads to
reversal of hypermethylation and reactivation of
p16INK4a, RARβ, and MGMT genes [34]. Thus, diet seems
to be an important factor in affecting the methylation sta-
tus of different genes implicated in cancer. It is also likely
that genes are differentially methylated in different ethnic
groups owing to the lifestyle and dietary differences.
Methylation of promoter in controls (BPH) may reflect
that epigenetic alteration of the gene has already occurred
and that they have acquired epigenetic malignant poten-
tial even though the pathological diagnosis classifies them
as benign [33]. Our results indicate that differences in
methylation pattern of TMS1/ASC in BPH among ethnic
groups might explain the differences among different
racial groups in susceptibility to prostate cancer. Thus it
seems that the epigenetic make up of different ethnic
groups would determine the risk to prostate cancer patho-
genesis.
Table 3: Overall and race-specific frequencies of TMS1/ASC gene methylation in prostate-cancer patients and BPH controls, with age-
adjusted odds-ratio estimates of the relative risk of prostate cancer associated with TMS1/ASC gene methylation.
Number and (%) of tissues with TMS1/ASC methylation Age-adjusted odds ratio* (95% CI)
Patients Prostate Cancer Control (BPH) P-value
All 42/66 (63.6) 12/34 (35.3) 3.7 (1.4 – 9.4) 0.008
Blacks 14/21 (66.7) 7/12 (58.3) 1.1 (0.2 – 5.5) 0.91
Whites  28/45 (62.2) 5/22 (22.7) 7.6 (2.1 – 27.3) 0.002
* For the overall odds ratio estimate, we modeled the logit of the probability of being a case (p), as a function of TMS1/ASC gene methylation and 
age: ln [p/(1-p)] = b0 + b1 × TMS1/ASC + b2 × Age. For the race-specific age-adjusted odds-ratio estimates, the following model was fitted: ln [p/(1-
p)] = b0 + b1 × TMS1/ASC + b2 × Age + b3 × Race + b4 × TMS1/ASC × Race. The interaction term TMS1/ASC*Race was marginally significant (p = 
0.068).
Table 4: Effect of TMS1/ASC gene methylation on clinical stage (II or III), and Gleason score (6 or 7).
Number and (%) of tissues 
with TMS1/ASC methylation
Age-adjusted odds-ratio* 
(95% CI)
P-value
Clinical stage
II (reference) 28/42 (66.7)
III 11/19 (57.9) 0.7 (0.2 – 2.1) 0.53
Gleason score
6 (reference) 14/26 (53.9)
7 23/32 (71.9) 2.3 (0.7 – 7.2) 0.15
* Age-adjusted relative risk estimates of stage III vs. II, or Gleason score 7 vs. 6, derived from logistic model ln (p/q) = b0 + b1 × TMS1/ASC + b2 × 
Age, where p is either the probability of having stage III disease or of having Gleason score 7, and q = (1-p) is the probability of the other category.Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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There did not appear to be a significant relationship
between TMS1/ASC methylation status and patient's age.
On our limited dataset there was a trend towards associa-
tion between TMS1/ASC methylation and Gleason score 7
or higher (odds-ratio 2.3). Though the relationship was
not statistically significant it possibly suggests a worse
prognosis as patients with Gleason score 7 do worse that
those with Gleason score 6. Many of our patient samples
showed partial methylation status – this could be due to
presence of normal fibroblasts, endothelial cells, inflam-
matory cells and non malignant prostate tissue surround-
ing the tumor. Tumors where TMS1/ASC was not found to
be methylated could involve other genes in the apoptotic
pathway. Use of pathway specific cDNA microarrays may
help in determining the individual genes affected.
In summary our study has shown that TMS1/ASC, a pro-
apoptotic gene, is silenced by hypermethylation of the
CpG islands in the promoter region. This transcriptional
repression is relieved by treatment with a demethylating
agent (5-Aza-2'-deoxycytidine). Frequent methylation of
TMS1/ASC in prostate cancer suggests this gene may be
important in pathogenesis of prostate cancer and can be a
target of pharmacologic demethylation in clinical trials.
TMS1/ASC methylation patterns show significant ethnic
differences. Our findings provide a novel insight into the
molecular determinants of tumor growth that may under-
lie the ethnic differences in prostate cancer incidence and
clinical behavior. Further studies are needed to find out if
this has any significant clinical implications in the devel-
opment of novel diagnostic approaches for biologically
aggressive prostate cancer from diverse racial origin.
Methods
Cell lines
LNCaP, PC3 and DU145 prostate cancer cells, obtained
from American Type Culture Collection were maintained
in DMEM (Invitrogen, Carlsbad, CA) and supplemented
with 10% fetal bovine serum in a humidified incubator at
37°C with an atmosphere of 5% CO2.
Tissue samples
This IRB-approved study involved patients who either had
radical prostatectomy between 1998 and 2002 for pros-
tate cancer or trans-urethral resection between 2000 and
2002 for benign prostatic hypertrophy. Sixty-six prostate
cancer and 34 benign prostatic hyperplasia (BPH)
patients were selected for the study. The prostate-cancer
cases and the BPH controls represented all patients who
had archived tissue available for study. The characteristics
of these two groups are shown in Table 2. The Whites were
of northern European descent and did not include His-
panics
Table 5: Risk of prostate cancer in relation to gene methylation, total patients and by race.
Number and (%) of tissues with gene methylation Age-adjusted
Gene Prostate Cancer Control (BPH) odds ratio* (95% CI) P-value
TMS1/ASC 42/66 (63.6) 12/34 (35.3) 3.7 (1.4 – 9.4) 0.008
Blacks 14/21 (66.7) 7/12 (58.3) 1.1 (0.2 – 5.5) 0.914
Whites 28/45 (62.2) 5/22 (22.7) 7.6 (2.1 – 27.3) 0.002
GSTP1 46/66 (69.7) 1/34 (2.9) 69.7 (8.7 – 558.7) <0.0001
Blacks 15/21 (71.4) 0/12 (0.0) --
Whites 31/45 (68.9) 1/22 (4.6) --
CD44 46/66 (69.7) 13/34 (38.2) 2.7 (1.1 – 6.9) 0.033
Blacks 14/21 (66.7) 4/12 (33.3) 2.9 (0.6 – 14.4) 0.190
Whites 32/45 (71.1) 9/22 (40.9) 2.6 (0.9 – 8.1) 0.093
ECAD 39/66 (59.1) 5/34 (14.7) 7.9 (2.6 – 24.0) <0.001
Blacks 15/21 (71.4) 2/12 (16.7) 10.9 (1.7 – 70.9) 0.013
Whites 24/45 (53.3) 3/22 (13.6) 7.2 (1.8 – 29.2) 0.006
RASSF1A 34/66 (51.5) 6/34 (17.7) 4.1 (1.5 – 11.8) 0.008
Blacks 10/21 (47.6) 1/12 (8.3) 8.6 (0.9 – 84.7) 0.064
Whites 24/45 (53.3) 5/22 (22.7) 3.2 (0.9 – 10.7) 0.056
EBR 49/66 (74.2) 23/34 (67.7) 1.3 (0.5 – 3.5) 0.582
Blacks 15/21 (71.4) 7/12 (58.3) 1.9 (0.4 – 9.5) 0.460
Whites 34/45 (75.6) 16/22 (72.7) 1.1 (0.3 – 3.7) 0.912
* For the overall odds ratio estimate, we modeled the logit of the probability of being a case (p), as a function of methylation in the particular gene 
and age: ln [p/(1-p)] = b0 + b1 × gene + b2 × Age. For the race-specific age-adjusted odds-ratio estimates, the following model was fitted: ln [p/(1-p)] 
= b0 + b1 × gene + b2 × Age + b3 × Race + b4 × gene × Race. The interaction between TMS1/ASC and race was marginally significant (p = 0.068), 
while the interactions between each other genes and race were not statistically significant at the 5% level (that is, corresponding p-values were 
greater than 0.454).Molecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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Drug treatment of prostate cancer cell lines
For 5-Aza-2'-deoxycytidine (Sigma, St. Louis, MO) and
Trichostatin A (TSA) (Sigma St. Louis, MO) treatment,
LNCaP cells were grown in 100 mm dishes and treated
with 1 µm 5-Aza-2'-deoxycytidine and 300 nm TSA. 5-
Aza-2'-deoxycytidine treatment was continued for 7 con-
secutive days where as TSA treatment was done for 6 hours
on the final day. RNA, DNA and chromatin were extracted
on day 7.
RNA extraction and reverse transcriptase PCR (RT-PCR)
RNA was extracted from the cell lines using RNA Stat 60
(Tel-Test Inc. Friendswood, TX) as per the manufacturer's
instructions. cDNA was prepared from 10 µg of RNA using
the Reverse Transcription System from Promega (Madi-
son, WI) using random primers. Two µl of the cDNA was
used for the PCR reaction. The primers and PCR condi-
tions used are mentioned in Table 1. Human beta actin
(ACTB) was used as the housekeeping gene for loading
control.
DNA extraction, bisulfite treatment and methylation-
specific PCR (MS-PCR)
Methylation patterns of the prostate cancer cell lines and
the tissue samples were analyzed by MS-PCR of bisulfite
treated DNA. DNA was extracted from the prostate cancer
cell lines using DNA Stat 60 (Tel-Test Inc. Friendswood,
TX.). DNA from archived paraffin blocks was isolated
using a QIAmp mini-kit (QIAGEN, CA) as per the manu-
facturer's protocol. This method successfully isolates DNA
suitable for PCR amplification from fixed tissues.
Genomic DNA was treated with sodium bisulfite under
conditions that converts unmethylated cytosine to uracil
while the 5-methylcytosine remains unchanged [35,36].
The bisulfite conversion reaction was carried out by incu-
bating 5 µg DNA with a 5 M bisulfite solution and 100
mM hydroquinone, pH 5.0 at 50°C for 4 hours. This was
followed by desulfonation by addition of 3 M NaOH, and
desalting using a QIAquick column (Qiagen, CA). MS-
PCR was performed using methylated and unmethylated
TMS1/ASC primers (Accession No. AF184072). The prim-
ers described by Virmani et. al., [15] located in the pro-
moter region were used in the study. Details of the
primers used are mentioned in Table 1. Human placental
DNA was methylated in vitro using sssI DNA Methylase
(NEB) and bisulfite treated for use as a positive control.
Bisulfite sequencing
Five µl of the bisulfite treated DNA from LNCaP, PC3 and
Du145 cell lines was amplified by PCR using the BST
sequencing primers. The primers were designed to
amplify both methylated as well as unmethylated DNA.
The PCR products were run on a 2% agarose gel and the
desired band was gel purified using Promega SV gel puri-
fication Kit (Promega Corp). The Thermo Sequenase Radi-
olabeled Terminator Cycle Sequencing Kit (USB Corp.,
Cleveland, OH) was used for sequencing using forward
and reverse primers. The sequencing gel was dried, and
radioactive bands were analyzed using Storm phosphor
imager (GE Health Care).
Chromatin Immunoprecipitation (CHIP) and Real time 
PCR
Chromatin immunoprecipitation assays were carried out
with a kit from Upstate Biotechnology (Lake Placid, NY)
using the manufacturer's protocol and reagents except
that the reactions were scaled down ten-fold. Briefly, 2 ×
107 cells were incubated in 0.5% formaldehyde for ten
minutes to crosslink bound proteins, washed, lysed in
SDS lysis buffer and sonicated to 100–500 bp lengths. Ten
µl chromatin was mixed with 90 µl of ChIP dilution buffer
and precleared with Protein A agarose, and then the chro-
matin was incubated with anti acetylated H3 and H4 anti-
body overnight at 4°C. Thirty µl of Protein A agarose
beads was added and the chromatin was immunoprecipi-
tated 2 hours at 4°C. The supernatant (unbound chroma-
tin) and beads (bound chromatin) were separated. The
beads were washed five times with the buffers provided
and then the chromatin was eluted twice in 1%SDS in 0.1
M NaHCO3. Cross-linking was reversed by adding 5 M
NaCl and incubating at 65°C for at least 4 hours, follow-
ing which proteinase K digestion was carried out and DNA
was extracted with phenol/chloroform. DNA was ethanol
precipitated and dissolved in 100 µl of water.
Real time PCR was performed in triplicate using 5 µl of the
immunoprecipitated DNA using primers for TMS1/ASC
and GAPDH as a housekeeping gene. Quantitative PCR
was carried out in a reaction volume of 25 µl using iQ™
SYBR® Green Supermix (BioRad Laboratories, Hercules,
CA) on MyiQ™ Single-Color Real-Time PCR Detection
System (BioRad Laboratories, Hercules, CA). The final
reaction mixture contained 400 nmol/L of each primer.
PCR was done for 50 cycles at an annealing temperature
of 68°C for TMS1/ASC and 65°C for GAPDH. A standard
curve was prepared for both the genes using a serial dilu-
tion of sonicated human placental DNA (Sigma Chemical
Co.). Appropriate negative controls were included in each
run. Ratio of TMS1/ASC to GAPDH was calculated for
each sample.
Statistical analyses
SAS software (release 8.2, SAS Institute) was used for sta-
tistical analyses. Student's t test (Armitage, Berry & Mat-
thews 2001) was used to compare the average age in the
BPH and prostate-cancer groups. Logistic regression (Hos-
mer & Lemeshow, 2000) was used to determine the effect
of methylation in the particular gene on prostate cancer
risk, whether this effect was similar for Blacks and Whites,
and whether TMS1/ASC gene methylation was associatedMolecular Cancer 2006, 5:28 http://www.molecular-cancer.com/content/5/1/28
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with Gleason score, clinical stage, or age of prostate cancer
onset. In particular, since prostatic tumors with Gleason-
score values of 7 have a substantially worse clinical course
than those with values of Gleason score 6, and since few
patients (only 10%) had Gleason-score values other than
6 or 7, we used logistic regression to compare the relative
frequency of TMS1/ASC  methylation in tumors with
Gleason score 7 versus 6. For association with clinical
stage, we likewise compared TMS1/ASC methylation in
stage 3 versus stage 2 tumors because these two stages
comprised 93% of tumors studied. Since prostate-cancer
patients were on average 7 years younger than the BPH
controls, all of the odds-ratio estimates of relative risk
associated with a particular gene methylation were
adjusted for age as a continuous covariate in the logistic
regression analyses.
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